Bradykinin receptors in GtoPdb v.2023.1

Joseph Coulson; Réjean Couture; Alexander Faussner; Fernand Gobeil Jr; Fredrik Leeb-Lundberg; Francois Marceau; Werner Muller-Esterl; Doug Pettibone; Bruce Zuraw

doi:10.2218/gtopdb/F10/2023.1

Joseph Coulson University of Edinburgh
Réjean Couture Université de Montréal
Alexander Faussner Ludwig-Maximilians-Universität
Fernand Gobeil Jr Université de Sherbrooke
Fredrik Leeb-Lundberg Lunds Universitet
Francois Marceau Université Laval
Werner Muller-Esterl Johann Wolfgang Goethe-University
Doug Pettibone Merck Research Laboratories
Bruce Zuraw University of California San Diego

Abstract

Bradykinin (or kinin) receptors (nomenclature as agreed by the NC-IUPHAR subcommittee on Bradykinin (kinin) Receptors [92]) are activated by the endogenous peptides bradykinin (BK), [des-Arg⁹]bradykinin, Lys-BK (kallidin), [des-Arg¹⁰]kallidin, [Phospho-Ser⁶]-Bradykinin, T-kinin (Ile-Ser-BK), [Hyp³]bradykinin and Lys-[Hyp³]-bradykinin. Variation in pharmacology and activity of B₁ and B₂ receptor antagonists at species orthologs has been documented. icatibant (Hoe140, Firazir) is approved in North America and Europe for the treatment of acute attacks of hereditary angioedema. Inhibition of bradykinin with icatibant in COVID-19 infection is under clinical evaluation, with trial NCT05407597 expected to complete in mid 2023.

DOI: https://doi.org/10.2218/gtopdb/F10/2023.1